What is Veracyte's thereafter?

Veracyte (VCYT) reported thereafter of $21.02M in Q1 2026.

How has Veracyte's thereafter changed year-over-year?

Veracyte's thereafter decreased by 24.1% year-over-year, from $27.7M to $21.02M.

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Cash & equivalents$264.8M+41.0%

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Market cap$4.29B+10.7%

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept vcyt:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

What is Veracyte's thereafter?: Veracyte (VCYT) reported thereafter of $21.02M in Q1 2026.
How has Veracyte's thereafter changed year-over-year?: Veracyte's thereafter decreased by 24.1% year-over-year, from $27.7M to $21.02M.